Lupin gains 3% on USFDA approval for generic Corgard tablets
The company has received final approval from the US health regulator to market generic Nadolol tablets, used for treatment of hypertension, in the American market.
 "Lupin gains 3% on USFDA approval for generic Corgard tablets")
premium
Lupin was trading 3% higher at Rs 1,068 on BSE at 09:30 AM after the pharmaceutical company said it has received final approval from the US health regulator to market generic Nadolol tablets, used for treatment of hypertension, in the American market.
“The company has received final approval for its Nadolol tablets USP 20 mg, 40 mg and 80 mg from the United States Food and Drug Administration (USFDA) to market a generic version of US WorldMeds, LLC Corgard Tablets, 20 mg, 40 mg and 80 mg,” Lupin said in a press release on Monday after market hours.
The product is a generic version of US WorldMeds LLC's Corgard tablets in the same strengths, it added.
The tablets are indicated for management of patients with angina pectoris and for the treatment of hypertension.
According to IMS MAT June 2017 data, Nadolol tablets USP had annual sales of approximately USD 109.8 million in the US.
“The company has received final approval for its Nadolol tablets USP 20 mg, 40 mg and 80 mg from the United States Food and Drug Administration (USFDA) to market a generic version of US WorldMeds, LLC Corgard Tablets, 20 mg, 40 mg and 80 mg,” Lupin said in a press release on Monday after market hours.
The product is a generic version of US WorldMeds LLC's Corgard tablets in the same strengths, it added.
The tablets are indicated for management of patients with angina pectoris and for the treatment of hypertension.
According to IMS MAT June 2017 data, Nadolol tablets USP had annual sales of approximately USD 109.8 million in the US.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%